Ikaria Holdings will merge with INO Therapeutics in a transaction valued at approximately $670 million.
INO Therapeutics is being acquired from The Linde Group, which will retain an equity position in the new entity. The combined company, which will be called Ikaria Holdings, will focus on therapeutic gases and critical care medicine. Its corporate headquarters will be in Clinton, NJ.
"The merger of Ikaria and INO Therapeutics creates a fully integrated critical care therapeutics company with more than 300 employees, exceptional growth opportunities, and the capability to significantly improve critical care for newborns and other patients in thousands of hospitals around the world," says David Shaw, chairman and CEO-designate of the combined Ikaria entity.